Extended Data Fig. 4: TCR repertoire characterization in peripheral blood and tumor by PSA0 at 1-year.
From: Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial
(a, b) Total T-cells expanded in tumor (a) or peripheral blood at prostatectomy (b, D50) versus fraction of peripheral clones expanded and detected intratumorally. (c, d) Total unique T-cell clonotypes expanded in tumor (c) or peripheral blood at prostatectomy (d, D50) versus fraction of peripheral clones expanded and detected intratumorally. Each point on the scatter plots represents a patient. Blue dots indicate responders for a given outcome and red dots indicate non-responders.
